In this episode, we talk to Scott Berry, President and Senior Statistical Scientist at Berry Consultants - a pioneer in adaptive and Bayesian clinical trial design. With more than 25 years of experience designing trials for pharma, biotech, and government agencies, Scott has helped reshape how we think about learning in drug development.

We explore what it really means to “learn as you go” in clinical trials - from the limitations of the traditional frequentist model to the promise of adaptive and Bayesian designs that evolve with the data. Scott breaks down why these methods can de-risk programs, optimize capital use, and accelerate decision-making, while still maintaining scientific and regulatory rigor.

We also discuss adoption barriers, cultural inertia in big pharma and the evolving stance of regulators. Along the way, Scott shares insights on trial efficiency, Bayesian thinking in investment committees, and why he expects future of drug development to look much more Bayesian than it is today.

If you want to connect with us:
Linkedin: https://www.linkedin.com/company/cures-capital-podcast

If you prefer to get the episodes in an audio form, you can get the podcast from Spotify and Apple Podcasts, just search for Cures & Capital.

If you want to connect with Scott or follow up on some of his work:
Linkedin: https://www.linkedin.com/in/scott-berry-52b8025b/
Berry Consultants: https://www.berryconsultants.com/
In the Interim: https: https://www.berryconsultants.com/podcast

Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.